SecBot SecBot
Insider Cluster (5 insiders) ·Filed Aug 12, 2026

REPL

Replimune Group, Inc.
MIXED
Impact 6/10
Horizondays Processed3mo ago
Insider cluster: 4 insiders, $0.9M total
Actionable Insight ◆ Mixed

The C-suite sells are noise, small dollar amounts likely tied to tax withholding or 10b5-1 plans. The real signal is Baker Brothers' $33M open-market purchase at the offering price, which is a massive vote of confidence. This offsets the bearish dilution narrative from the $150M offering. Traders should watch for additional insider buying from Baker or other directors in the coming days. The stock may find support near the $12.06 offering price given Baker's floor.

DirectionMixed
Confidencehigh
Horizondays

TUDRIQEV

● Neutral Named in this insider cluster
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already approved and commercially available in the U.S. since October 2026.
Next catalyst
None dated

What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$15.19
T+0 close · Aug 12, 2026 · via day close
Latest settled
+39.27%
T+60 · $21.16
Vs SPY
+44.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $15.19entry
  2. T+1 · 3mo ago −1.45%α −1.25% · $14.97
  3. T+5 · 3mo ago −7.50%α −5.54% · $14.05
  4. T+20 · 2mo ago −14.94%α −13.20% · $12.92
  5. T+60 · 11d ago +39.27%α +44.51% · $21.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Replimune insiders (CEO, CFO, CMO, CAO) sold $906K in open-market sales on August 10, 2026, the same day as a $150M dilutive offering priced at $12.06. The sales are small relative to the $1.1B market cap (0.08%), but the timing, coinciding with the offering, suggests insiders were selling into the offering price. Critically, Baker Brothers, a director and the company's largest holder, purchased $33M in open-market shares on August 11, 2026, at the offering price, signaling confidence in the post-dilution value. The cluster is mixed: C-suite sells are routine liquidity (likely 10b5-1 or tax-related), while Baker's massive buy is a strong bullish signal that partially offsets the dilution narrative.

Key Financial Metrics

Direction
mixed
Total Value
$33.9M
Insiders
5

Key Facts

  • CEO Sushil Patel sold 39,341 shares for $510K on 2026-08-10
  • CFO Emily Hill sold 11,448 shares for $148K on 2026-08-10
  • CMO Konstantinos Xynos sold 11,447 shares for $148K on 2026-08-10
  • CAO Andrew Schwendenman sold 7,632 shares for $99K on 2026-08-10
  • Baker Brothers (Director) purchased 2,736,340 shares for $33M on 2026-08-11
  • Total insider sales of $906K represent 0.08% of $1.1B market cap
  • Baker Brothers' $33M purchase is 3.0% of market cap
  • The $150M offering closed on 2026-08-10 at $12.06 per share

Financial Impact

Insider sales of $906K (0.08% of market cap) are trivial; Baker Brothers' $33M purchase (3.0% of market cap) is highly material and signals strong insider conviction

dilutioninsider ownership

Risk Factors

  • The $150M offering dilutes existing shareholders by ~13%, which could weigh on the stock near term
  • Baker Brothers' purchase is a single event; if they sell in the future, it would be a negative signal
  • The company has no product revenue and requires confirmatory trials for TUDRIQEV's accelerated approval

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
79% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-REPL-1786612060363

Track record

32 reports on REPL

Performance horizon

9 of 13 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 13 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
  2. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  5. Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  6. Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  7. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
  8. Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
  10. Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
Showing 10 of 32

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026